Relief Therapeutics Holding AG (Relief Therapeutics Holding AG Stock Quote, Charts, News, Analysts, Financials OTC:RLFTD) is a biopharma company focused on the treatment of metabolic, dermatological and pulmonary rare diseases.
The company is based in Geneva and is developing candidate RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis and chronic berylliosis.
Last week, Relief Therapeutics filed its 2022 annual report, posting revenue of $6.1 million compared to $3.3 million in 2021. EBITDA was a loss of $63K versus a loss of $752K in 2021, while the operating loss was $52.0 million compared to $34.3 million a year ago. The company finished the year with $188.8 million in total assets, $19.2 million in total cash and $43.4 million in total debt.
Relief completed a 1:400 share consolidation recently and is aiming to get a listing on the Nasdaq Stock Market.
“Implementing a consolidation of our shares will enable Relief to meet the minimum price criteria needed in order to list on the Nasdaq,” said Jack Weinstein, chief executive officer at Relief Therapeutics. “Listing on a stock exchange in the U.S. will provide greater liquidity and broader access to the capital needed to expedite the development of our pipeline, obtain clinical validation of our potential therapies and further execute our business development strategy,” said the company in an April 4 press release.
Relief Therapeutics also has candidate RLF-TD011, a hypochlorous acid topical sprayable solution for the treatment of wounds, local inflammation and healing in epidermolysis bullosa.
RLFTD currently has a market cap of $45 million and its shares have been trading in a 52-week range of $4.08-$24.67 per share.